Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: InMed Pharmaceuticals Inc. INM

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at H.C. Wainwright 25th Annual Global Investment Conference

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing, and commercialization of rare cannabinoids and cannabinoid analogs, today announced its participation in the H.C. Wainwright Global Investment Conference, which is taking place Sept. 11-13, 2023, in New … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Water Tower Research Fireside Chat Series

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that Jerry Griffin, VP of Sales and Marketing for InMed’s subsidiary BayMedica LLC, a leading … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on BayMedica Rare Cannabinoid Business

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today provided a commercial and manufacturing update on its subsidiary BayMedica LLC, a leading supplier of bioidentical rare cannabinoids to … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) 755-201-EB Trial Demonstrates Clinically Important Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced safety and efficacy results from its phase 2 clinical trial. The purpose of the trial, called “755-201-EB,” was … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Sponsored Research Presented at Canadian Neuroscience Meeting

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids, today announced that results from a neurodegenerative disease study were presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Participate in Virtual Investor Events Next Week

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be represented at two upcoming investor events. The company announced that members of its executive team will be participating … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO Featured in Upcoming Water Tower Research Fireside Chat

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be represented at an upcoming Water Tower Research Fireside Chat Series. The company announced that CEO Eric A. Adams … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the third quarter of the fiscal year 2023, which ended March 31, 2023. “The third … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Peer-Reviewed Study Results Published

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has announced that results of its study have been published in the “International Journal of Molecular Sciences.” The study was designed … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q2 2023 Financial, Corporate Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting on its second quarter of fiscal year 2023, the period that ended Dec. 31, 2022. Highlights of the report … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment